+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Breast Cancer Liquid Biopsy Market by Technology (BEAMing, Digital PCR, Next Generation Sequencing), Biomarker Type (Circulating Free DNA, Circulating Tumor Cells, Circulating Tumor DNA), Application, Sample Type, End User, Cancer Stage - Global Forecast 2025-2030- Product Image
Breast Cancer Liquid Biopsy Market by Technology (BEAMing, Digital PCR, Next Generation Sequencing), Biomarker Type (Circulating Free DNA, Circulating Tumor Cells, Circulating Tumor DNA), Application, Sample Type, End User, Cancer Stage - Global Forecast 2025-2030- Product Image
Sale

Breast Cancer Liquid Biopsy Market by Technology (BEAMing, Digital PCR, Next Generation Sequencing), Biomarker Type (Circulating Free DNA, Circulating Tumor Cells, Circulating Tumor DNA), Application, Sample Type, End User, Cancer Stage - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011425
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The breast cancer liquid biopsy market is rapidly advancing, propelled by technological innovation and expanding clinical utility. Senior decision-makers are navigating a landscape defined by non-invasive diagnostics, real-time biomarker analysis, and shifting regulatory requirements—all of which are reshaping breast cancer care.

Market Snapshot: Breast Cancer Liquid Biopsy Market Overview

The Breast Cancer Liquid Biopsy Market grew from USD 589.92 million in 2024 to USD 705.85 million in 2025. It is expected to continue growing at a CAGR of 19.49%, reaching USD 1.71 billion by 2030.

Scope & Segmentation

  • Technology Platforms: Covers BEAMing for highly sensitive mutation detection; digital PCR with chip-based and droplet methodologies; next generation sequencing, including targeted, whole exome, and whole genome approaches; and qPCR platforms featuring multiplex and real-time quantitative assays.
  • Biomarker Types: Encompasses circulating free DNA, circulating tumor cells, circulating tumor DNA, and exosomes, which are subdivided into exosomal protein and exosomal RNA.
  • Clinical Applications: Includes early detection through high-risk and population screening, minimal residual disease monitoring in post-treatment settings, recurrence monitoring, and guiding personalized treatment selection.
  • Sample Types: Market assessment spans plasma (the predominant analyte source), as well as saliva, serum, and urine—each supporting specific use cases or operational needs.
  • End Users: Insights target diagnostic laboratories, hospitals, and research institutes seeking advanced liquid biopsy integration into clinical workflows.
  • Cancer Stages: Segmentation covers both early-stage and advanced disease, including metastatic presentations, to address a wide clinical spectrum.
  • Regional Markets: Evaluation includes the Americas (United States: California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; plus Canada, Mexico, Brazil, and Argentina), Europe, Middle East & Africa (with specific coverage of Western and emerging market dynamics), and Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, and Taiwan).
  • Company Analysis: Profiles Roche Diagnostics International AG, Guardant Health, Inc., Natera, Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Exact Sciences Corporation, Sysmex Inostics GmbH, Qiagen N.V., Bio-Rad Laboratories, Inc., and Biocept, Inc.

Key Takeaways for Senior Decision-Makers

  • Liquid biopsy enables less invasive and more comprehensive disease surveillance compared to traditional tissue biopsies, supporting continuous patient monitoring through real-time biomarker assessment.
  • Adoption is accelerating, driven by increasing clinical validation and peer-reviewed research highlighting utility in early detection, treatment monitoring, and recurrence risk assessment.
  • Regulatory agencies are evolving frameworks and guidance to streamline market entry, while reimbursement landscapes are adapting to reflect demonstrated clinical and economic value.
  • Strategic partnerships, including co-development deals between technology vendors and biotech specialists, are shaping competitive dynamics and market expansion strategies.
  • Regional differences in reimbursement and adoption, particularly between established Western markets and emerging Asia-Pacific or Middle Eastern regions, require regionally adaptive go-to-market approaches.
  • Investment in modular instrument design and locally sourced reagents is building resilience against supply disruptions and supporting tariff-related procurement challenges.

Tariff Impact on Supply Chains and Resilience

Recent tariff measures in the United States have introduced new cost pressures by raising import duties on key reagents and instrumentation components. Stakeholders are responding by seeking domestic manufacturing partnerships, validating alternative reagent sources, and implementing modular product designs to mitigate pricing volatility and production bottlenecks.

Methodology & Data Sources

This report utilizes a dual approach: robust secondary research from clinical registries, regulatory filings, and industry sources, combined with in-depth primary interviews with oncologists, laboratory leaders, and executives. Multiple rounds of validation ensure the accuracy and reliability of all findings.

Why This Report Matters

  • Offers senior leaders actionable insights for optimizing portfolios, navigating regulatory shifts, and building resilient supply strategies in the breast cancer liquid biopsy market.
  • Equips decision-makers with detailed segmentation, key company profiles, and regional market dynamics to support tailored growth and investment planning.
  • Supports strategic collaboration by revealing innovation hotspots and emerging market opportunities for expansion or partnership.

Conclusion

With the convergence of technology, clinical evidence, and strategic partnership, the breast cancer liquid biopsy sector is entering a period of significant transformation. Leaders armed with focused insights and adaptable strategies will be best positioned for sustainable growth and innovation.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advances in ultra-sensitive methylation-based ctDNA assays improving minimal residual disease detection in breast cancer
5.2. Expansion of point-of-care liquid biopsy platforms for rapid monitoring of therapy response in metastatic breast cancer
5.3. Collaboration between pharmaceutical and diagnostics companies to co-develop companion liquid biopsy tests for targeted therapies
5.4. Emergence of exosome-based liquid biopsy tests offering comprehensive biomarker profiling and drug resistance insights
5.5. Regulatory approvals of FDA-designated breakthrough breast cancer liquid biopsy tests accelerating commercial adoption
5.6. Development of standardized preanalytical workflows to reduce variability in sample collection and ctDNA analysis
5.7. Increasing reimbursement coverage and health economic evidence supporting routine liquid biopsy use in clinical practice
5.8. Integration of multi-omics approaches combining ctDNA, exosome RNA, and protein markers for holistic disease monitoring
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Breast Cancer Liquid Biopsy Market, by Technology
8.1. Introduction
8.2. BEAMing
8.3. Digital PCR
8.3.1. Chip Based Digital PCR
8.3.2. Droplet Digital PCR
8.4. Next Generation Sequencing
8.4.1. Targeted Sequencing
8.4.2. Whole Exome Sequencing
8.4.3. Whole Genome Sequencing
8.5. qPCR
8.5.1. Multiplex Quantitative PCR
8.5.2. Real Time Quantitative PCR
9. Breast Cancer Liquid Biopsy Market, by Biomarker Type
9.1. Introduction
9.2. Circulating Free DNA
9.3. Circulating Tumor Cells
9.4. Circulating Tumor DNA
9.5. Exosomes
9.5.1. Exosomal Protein
9.5.2. Exosomal RNA
10. Breast Cancer Liquid Biopsy Market, by Application
10.1. Introduction
10.2. Early Detection
10.2.1. High Risk Screening
10.2.2. Population Screening
10.3. Minimal Residual Disease
10.3.1. Post Treatment Surveillance
10.4. Recurrence Monitoring
10.5. Treatment Selection
11. Breast Cancer Liquid Biopsy Market, by Sample Type
11.1. Introduction
11.2. Plasma
11.3. Saliva
11.4. Serum
11.5. Urine
12. Breast Cancer Liquid Biopsy Market, by End User
12.1. Introduction
12.2. Diagnostic Laboratories
12.3. Hospitals
12.4. Research Institutes
13. Breast Cancer Liquid Biopsy Market, by Cancer Stage
13.1. Introduction
13.2. Advanced Stage
13.2.1. Metastatic Disease
13.3. Early Stage
14. Americas Breast Cancer Liquid Biopsy Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Breast Cancer Liquid Biopsy Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Breast Cancer Liquid Biopsy Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Roche Diagnostics International AG
17.3.2. Guardant Health, Inc.
17.3.3. Natera, Inc.
17.3.4. Illumina, Inc.
17.3.5. Thermo Fisher Scientific Inc.
17.3.6. Exact Sciences Corporation
17.3.7. Sysmex Inostics GmbH
17.3.8. Qiagen N.V.
17.3.9. Bio-Rad Laboratories, Inc.
17.3.10. Biocept, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. BREAST CANCER LIQUID BIOPSY MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 6. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. BREAST CANCER LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. BREAST CANCER LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. BREAST CANCER LIQUID BIOPSY MARKET: RESEARCHAI
FIGURE 28. BREAST CANCER LIQUID BIOPSY MARKET: RESEARCHSTATISTICS
FIGURE 29. BREAST CANCER LIQUID BIOPSY MARKET: RESEARCHCONTACTS
FIGURE 30. BREAST CANCER LIQUID BIOPSY MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. BREAST CANCER LIQUID BIOPSY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MULTIPLEX QUANTITATIVE PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MULTIPLEX QUANTITATIVE PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REAL TIME QUANTITATIVE PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REAL TIME QUANTITATIVE PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING FREE DNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING FREE DNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL PROTEIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL PROTEIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL RNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL RNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HIGH RISK SCREENING, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HIGH RISK SCREENING, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POPULATION SCREENING, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POPULATION SCREENING, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POST TREATMENT SURVEILLANCE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POST TREATMENT SURVEILLANCE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PLASMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERUM, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY METASTATIC DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY METASTATIC DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 159. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 160. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 161. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2024 (USD MILLION)
TABLE 162. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2025-2030 (USD MILLION)
TABLE 163. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 164. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 165. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2024 (USD MILLION)
TABLE 166. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2025-2030 (USD MILLION)
TABLE 167. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
TABLE 168. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
TABLE 169. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2024 (USD MILLION)
TABLE 170. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2025-2030 (USD MILLION)
TABLE 171. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 172. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 173. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2024 (USD MILLION)
TABLE 174. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2025-2030 (USD MILLION)
TABLE 175. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2018-2024 (USD MILLION)
TABLE 176. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2025-2030 (USD MILLION)
TABLE 177. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 178. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 179. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2024 (USD MILLION)
TABLE 182. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2025-2030 (USD MILLION)
TABLE 183. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
TABLE 184. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2025-2030 (USD MILLION)
TABLE 185. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 186. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 187. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2024 (USD MILLION)
TABLE 188. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2025-2030 (USD MILLION)
TABLE 189. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 190. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 191. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2024 (USD MILLION)
TABLE 192. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2025-2030 (USD MILLION)
TABLE 193. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
TABLE 194. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
TABLE 195. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2024 (USD MILLION)
TABLE 196. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2025-2030 (USD MILLION)
TABLE 197. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 198. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 199. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2024 (USD MILLION)
TABLE 200. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2025-2030 (USD MILLION)
TABLE 201. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2018-2024 (USD MILLION)
TABLE 202. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2025-2030 (USD MILLION)
TABLE 203. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 204. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 205. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2024 (USD MILLION)
TABLE 208. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2025-2030 (USD MILLION)
TABLE 209. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
TABLE 210. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2025-2030 (USD MILLION)
TABLE 235. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
TABLE 236. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2024 (USD MILLION)
TABLE 260. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2025-2030 (USD MILLION)
TABLE 261. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
TABLE 262. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2024 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2025-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2025-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 292. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2024 (USD MILLION)
TABLE 298. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2024 (USD MILLION)
TABLE 302. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2025-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 304. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 305. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2024 (USD MILLION)
TABLE 306. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2025-2030 (USD MILLION)
TABLE 307. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2018

Samples

Loading
LOADING...

Companies Mentioned

  • Roche Diagnostics International AG
  • Guardant Health, Inc.
  • Natera, Inc.
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • Exact Sciences Corporation
  • Sysmex Inostics GmbH
  • Qiagen N.V.
  • Bio-Rad Laboratories, Inc.
  • Biocept, Inc.

Table Information

Report AttributeDetails
No. of Pages199
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 705.85 Million
Forecasted Market Value ( USD ) by 2030 $ 1710 Million
Compound Annual Growth Rate19.4%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Breast Cancer Liquid Biopsy Testing Devices Market by Technology, Application, End User, Test Type, Sample Type, Indication, Distribution Channel - Global Forecast 2025-2030 - Product Image

Breast Cancer Liquid Biopsy Testing Devices Market by Technology, Application, End User, Test Type, Sample Type, Indication, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Breast Cancer Liquid Biopsy Market Report by Product Services, Circulating Biomarker, End User, and Region 2025-2033 - Product Image

Breast Cancer Liquid Biopsy Market Report by Product Services, Circulating Biomarker, End User, and Region 2025-2033

  • Report
  • 150 Pages
  • Global
From
Breast Cancer Liquid Biopsy Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032 - Product Image

Breast Cancer Liquid Biopsy Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032

  • Report
  • 179 Pages
  • Global
From
Breast Cancer Liquid Biopsy - Global Strategic Business Report - Product Image

Breast Cancer Liquid Biopsy - Global Strategic Business Report

  • Report
  • 217 Pages
  • Global
From
Breast Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report by Circulating Biomarkers (Circulating Tumor Cells, Circulating Cell-free DNA, Extracellular Vesicles), Application, Region, and Segment Forecasts, 2025-2030 - Product Image

Breast Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report by Circulating Biomarkers (Circulating Tumor Cells, Circulating Cell-free DNA, Extracellular Vesicles), Application, Region, and Segment Forecasts, 2025-2030

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.